Triatomic Management’s Novo Nordisk NVO Stock Holding History

Triatomic Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-140,200	Closed	-$12.7M	–	53
2023 Q3	$12.7M	Buy	+140,200	New	+$12.4M	8.81%	3

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Triatomic Management's NVO Position: Q4 2023 in Review

Triatomic Management sold out of Novo Nordisk (NVO) in Q4 2023, closing a stake of 500 shares — an estimated $45.5K sold.

Triatomic Management first reported a position in NVO in Q3 2023 and held it in 1 quarter. The position peaked at $45.5K in Q3 2023. 1,511 funds tracked by Wall St. Rank hold NVO as of Q4 2023.

Triatomic Management reported no remaining Novo Nordisk position as of Q4 2023 after selling out during the quarter.
Triatomic Management sold 500 Novo Nordisk shares in Q4 2023, an estimated $45.5K.
Triatomic Management first reported a position in Novo Nordisk in Q3 2023 and held it in 1 quarter.
Triatomic Management's Novo Nordisk position peaked at $45.5K in Q3 2023.
1,511 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2023.

Based on Triatomic Management's 13F filing for Q4 2023, filed 13 Feb 2024.